6CM
LUMO

683 Capital Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

683 Capital Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,510
Closed -$375K – 242
2020
Q4 		$375K Buy
+10,510
New +$181K 0.02% 144

Other funds holding LUMO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

683 Capital Management's LUMO Position: Q1 2021 in Review

683 Capital Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2021, closing a stake of 10,510 shares — an estimated $375K sold.

683 Capital Management first reported a position in LUMO in Q4 2020 and held it in 1 quarter. The position peaked at $375K in Q4 2020. 41 funds tracked by Wall St. Rank hold LUMO as of Q1 2021.

  • 683 Capital Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • 683 Capital Management sold 10,510 Lumos Pharma, Inc. Common Stock shares in Q1 2021, an estimated $375K.
  • 683 Capital Management first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • 683 Capital Management's Lumos Pharma, Inc. Common Stock position peaked at $375K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.